All Oncology News

Converting from ICD-9 to ICD-10 will result in information and financial losses to providers, report researchers from the University of Illinois at Chicago

The FDA has placed a full clinical hold on the development of the investigational telomerase inhibitor imetelstat following concerns over consistent low-grade liver function test (LFT) abnormalities

Evidence that demonstrates how best to implement newer value-based purchasing (VBP) programs like accountable care organizations (ACOs) and bundled payments is lacking

The US cancer care system is faced with increasing cuts to Medicare payments, the prospect of a dramatic increase in the number of patients with cancer, and proportionately fewer oncology specialists to treat them.

More oncology practices are looking to advanced practice nurses and other non-physician providers to meet the needs of their cancer patients.

New research suggests that spending on anticancer agents is moderating, going against national trends that suggest an uptick in the US prescription drug expenditures this year.

Ruxolitinib, a JAK1/2 inhibitor, is the first treatment to demonstrate efficacy in a phase III trial for patients with polycythemia vera (PV), a chronic, incurable blood cancer with limited treatment options

With the adoption of a patient engagement initiative, Gwinnett Medical Center in Atlanta was able to improve the billing experience for 86% of patients surveyed.

Repealing the sustainable growth rate (SGR) formula, a mechanism Congress enacted in 1997 to limit Medicare costs, is going to leave taxpayers with a bill of $60 billion from 2014 through 2019, and a total of $138 billion through 2024.

An immunotherapy drug for the treatment of prostate cancer, approved in the US in 2010, will soon be available in Europe.

Bucking a trend reported for many years, new compensation data suggest the gap between what primary care physicians are paid and what medical and surgical specialists are paid is decreasing.

A phase III study exploring the MET inhibitor onartuzumab as a treatment for patients with NSCLC is being stopped, following an interim analysis that suggested a lack of clinically meaningful efficacy.

Hospitals and medical centers that provide chemotherapy infusion services to their cancer patients on an outpatient basis generally get paid more than oncologists and hematologists who provide the same services in a private office.

Improvements in quality of care and reductions in hospitalizations were minimal

More and more solo practices are facing a transformation that is neither small nor simple in the current accountable care environment.

For the first time, physicians have a clearer understanding of the optimum age for prophylactic oophorectomy in patients with BRCA mutations who want to reduce their risk of ovarian, fallopian tube, and breast cancer.

In an interview with OncLive, Jeffrey S. Weber, MD, PhD, from the Moffitt Cancer Center, University of South Florida, Tampa, explored the utilization of molecular and immune-targeted therapies as treatments for patients with advanced melanoma.

Results from the final report of the 2013 Healthcare Information and Management Systems Society (HIMSS) Security Survey suggest that physician practices and health care organizations such as hospitals view their own staff members as the greatest source of patient information and confidentiality security breaches.

The Centers for Medicare & Medicaid Services (CMS) is caving to pressure from the American Hospital Association, the American Medical Association, and the Medical Group Management Association (MGMA) to conduct far more extensive end-to-end testing to assure proper adjudication and payment of claims as the October 1 deadline for the ICD-10 transition looms

The second-line administration of ramucirumab in combination with docetaxel has shown a statistically significant improvement in overall survival and progression-free survival compared with placebo plus docetaxel in patients with non-small cell lung cancer

Traditionally, palliative care for patients with cancer is geared towards end-of-life measures, but a new study from the Princess Margaret Cancer Center in Toronto suggests patients who receive palliative care earlier in their cancer therapy report improved quality of life and greater satisfaction.

Providing access to health information technology and health information exchanges isn't always enough to avoid ordering duplicative tests

High-tech eyewear could soon help surgeons remove tumors from patients with breast cancer or melanoma by allowing them to see the margins of tumors more accurately when a dye is used to fluoresce a tumor's borders.

To reduce the costs of cancer, community oncologists increase the use of evidence-based treatments, standardize care with pathways, transition away from fee-for-service, and change communication with patients about reasonable end-of-life care.

Giants of Cancer Care is now accepting nominations for the 2014 awards program.

Oncology practices looking to update their EHR to be ICD-10 compliant are facing an even greater cost than originally estimated.

Regional Cancer Care Associates will collaborate with OncLive to develop informative resources for oncology professionals that advance patient care.

Biopharmaceutical companies that administer patient assistance programs (PAPs) well in terms of service and support parameters seem to benefit from a halo effect among their oncologist customers, according to "PAP Utilization in Cancer Care," a Cogent Reports survey from Market Strategies International, a market research company.

The FDA has expanded the approval of ibrutinib to include the treatment of patients with chronic lymphocytic leukemia who have received at least one previous therapy.

Providers who are eligible to participate in the Centers for Medicare & Medicaid Services (CMS) electronic health record (EHR) incentive program have a one month reprieve to show that their practices are using the technology in a meaningfully useful way.